FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970343207> ?p ?o ?g. }

• W1970343207 endingPage "252" @default.
• W1970343207 startingPage "235" @default.
• W1970343207 abstract "The permeation of nucleosides across the plasma membrane of mammalian cells is complex and mediated by at least five distinct transporters that differ in their sensitivity to inhibitors and in their specificity for nucleosides. The basic properties and permeant specificity of these transporters are summarized in Table 3. It appears that there may be differences in the distribution of these transporters in tumors and normal tissues that might be exploited for chemotherapeutic purposes. The human tumor cell lines examined express predominantly the NBMPR-sensitive equilibrative transporter es which can be blocked by low concentrations of NBMPR and dipyridamole. It is reasonable to expect that tumors with transport properties similar to the CCRF-CEM and Rh28 cell lines (Table 1) that have no detectable NBMPR-insensitive transport activity will be highly susceptible to the therapeutic approach of combining a transport inhibitor such as dipyridamole or NBMPR with an inhibitor of de novo pyrimidine biosynthesis. On the other hand, this approach to therapy is unlikely to succeed against tumors with transport phenotypes similar to the WI-L2 cell line that may permit the salvage nucleosides in the presence of these inhibitors. The majority of tumor cells examined, however, fall between these extremes, and it is not yet known what level of NBMPR-insensitive transport activity can be tolerated without seriously compromising this therapeutic approach. With respect to normal tissues, the mature absorptive cells of the intestine have predominantly Na+-dependent nucleoside transporters that are insensitive to NBMPR and dipyridamole. The proliferating crypt cells also appear to have Na+-dependent nucleoside transport, although they may also have an NBMPR-sensitive component of transport (Belt, unpublished data). Bone marrow granulocyte-macrophage progenitor cells also appear to have one or more concentrative nucleoside transporters. Thus these tissues, which are most vulnerable to the toxicity of antimetabolites, may be able to salvage nucleosides in the presence of inhibitors of equilibrative transport and be protected from the toxicity of de novo synthesis inhibitors. It is likely, however, that a successful application of this therapeutic approach will require the analysis of the nucleoside transport phenotype of individual tumors in order to identify those patients that may benefit from such therapy. Since the development of antibodies (66–68) and cDNA probes (69, 70) for the various nucleoside transporters is currently underway in several laboratories, it is likely that analysis of the nucleoside transport phenotype of tumors from biopsy material will be feasible in the future." @default.
• W1970343207 created "2016-06-24" @default.
• W1970343207 creator A5049070798 @default.
• W1970343207 creator A5059408820 @default.
• W1970343207 creator A5085873078 @default.
• W1970343207 creator A5004838451 @default.
• W1970343207 date "1993-01-01" @default.
• W1970343207 modified "2023-10-09" @default.
• W1970343207 title "Nucleoside transport in normal and neoplastic cells" @default.
• W1970343207 cites W1029653837 @default.
• W1970343207 cites W123909038 @default.
• W1970343207 cites W1484764833 @default.
• W1970343207 cites W1522328415 @default.
• W1970343207 cites W1554834393 @default.
• W1970343207 cites W1966382131 @default.
• W1970343207 cites W1975314903 @default.
• W1970343207 cites W1976365732 @default.
• W1970343207 cites W1982924160 @default.
• W1970343207 cites W1991871309 @default.
• W1970343207 cites W1996935259 @default.
• W1970343207 cites W1997304549 @default.
• W1970343207 cites W1999524264 @default.
• W1970343207 cites W2003379948 @default.
• W1970343207 cites W2028309431 @default.
• W1970343207 cites W2031803566 @default.
• W1970343207 cites W2032903115 @default.
• W1970343207 cites W2044904966 @default.
• W1970343207 cites W2046104315 @default.
• W1970343207 cites W2051419983 @default.
• W1970343207 cites W2059181765 @default.
• W1970343207 cites W2061381435 @default.
• W1970343207 cites W2062189464 @default.
• W1970343207 cites W206819481 @default.
• W1970343207 cites W2068353719 @default.
• W1970343207 cites W2071940161 @default.
• W1970343207 cites W2093062860 @default.
• W1970343207 cites W2168594682 @default.
• W1970343207 cites W2316845778 @default.
• W1970343207 cites W2342742634 @default.
• W1970343207 cites W2407093367 @default.
• W1970343207 cites W2408362060 @default.
• W1970343207 cites W2414134892 @default.
• W1970343207 cites W2419000356 @default.
• W1970343207 cites W2443169085 @default.
• W1970343207 cites W2462217852 @default.
• W1970343207 cites W41206836 @default.
• W1970343207 cites W616746582 @default.
• W1970343207 doi "https://doi.org/10.1016/0065-2571(93)90021-5" @default.
• W1970343207 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8356910" @default.
• W1970343207 hasPublicationYear "1993" @default.
• W1970343207 type Work @default.
• W1970343207 sameAs 1970343207 @default.
• W1970343207 citedByCount "160" @default.
• W1970343207 countsByYear W19703432072012 @default.
• W1970343207 countsByYear W19703432072013 @default.
• W1970343207 countsByYear W19703432072014 @default.
• W1970343207 countsByYear W19703432072017 @default.
• W1970343207 countsByYear W19703432072018 @default.
• W1970343207 countsByYear W19703432072019 @default.
• W1970343207 countsByYear W19703432072020 @default.
• W1970343207 countsByYear W19703432072022 @default.
• W1970343207 crossrefType "journal-article" @default.
• W1970343207 hasAuthorship W1970343207A5004838451 @default.
• W1970343207 hasAuthorship W1970343207A5049070798 @default.
• W1970343207 hasAuthorship W1970343207A5059408820 @default.
• W1970343207 hasAuthorship W1970343207A5085873078 @default.
• W1970343207 hasConcept C104317684 @default.
• W1970343207 hasConcept C126322002 @default.
• W1970343207 hasConcept C149011108 @default.
• W1970343207 hasConcept C185592680 @default.
• W1970343207 hasConcept C2776543447 @default.
• W1970343207 hasConcept C2776890861 @default.
• W1970343207 hasConcept C2780549722 @default.
• W1970343207 hasConcept C41625074 @default.
• W1970343207 hasConcept C502942594 @default.
• W1970343207 hasConcept C54355233 @default.
• W1970343207 hasConcept C55493867 @default.
• W1970343207 hasConcept C57947595 @default.
• W1970343207 hasConcept C71924100 @default.
• W1970343207 hasConcept C81885089 @default.
• W1970343207 hasConcept C86803240 @default.
• W1970343207 hasConcept C95444343 @default.
• W1970343207 hasConceptScore W1970343207C104317684 @default.
• W1970343207 hasConceptScore W1970343207C126322002 @default.
• W1970343207 hasConceptScore W1970343207C149011108 @default.
• W1970343207 hasConceptScore W1970343207C185592680 @default.
• W1970343207 hasConceptScore W1970343207C2776543447 @default.
• W1970343207 hasConceptScore W1970343207C2776890861 @default.
• W1970343207 hasConceptScore W1970343207C2780549722 @default.
• W1970343207 hasConceptScore W1970343207C41625074 @default.
• W1970343207 hasConceptScore W1970343207C502942594 @default.
• W1970343207 hasConceptScore W1970343207C54355233 @default.
• W1970343207 hasConceptScore W1970343207C55493867 @default.
• W1970343207 hasConceptScore W1970343207C57947595 @default.
• W1970343207 hasConceptScore W1970343207C71924100 @default.
• W1970343207 hasConceptScore W1970343207C81885089 @default.
• W1970343207 hasConceptScore W1970343207C86803240 @default.
• W1970343207 hasConceptScore W1970343207C95444343 @default.

• next